Disc Medicine, Inc. (NASDAQ:IRON) Stock Has Average Price Target of $110.18

Shares of Disc Medicine, Inc. (NASDAQ:IRON) have received an average rating of “Moderate Buy” from the thirteen research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $120.60.

Several research analysts have commented on the company. BMO Capital Markets lifted their price target on Disc Medicine from $100.00 to $120.00 and gave the stock an “outperform” rating in a research report on Monday. Wells Fargo & Company boosted their price objective on Disc Medicine from $86.00 to $124.00 and gave the company an “overweight” rating in a research note on Tuesday. Cantor Fitzgerald increased their price objective on Disc Medicine from $125.00 to $170.00 and gave the company an “overweight” rating in a report on Monday. HC Wainwright restated a “buy” rating and set a $120.00 target price on shares of Disc Medicine in a research report on Thursday, September 10th. Finally, Wedbush raised their target price on shares of Disc Medicine from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday.

Insider Buying and Selling at Disc Medicine

In related news, CEO John Quisel sold 33,000 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $79.15, for a total transaction of $2,611,950.00. Following the completion of the sale, the chief executive officer owned 226,064 shares in the company, valued at $17,892,965.60. This represents a 12.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rahul Khara sold 5,000 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $80.00, for a total transaction of $400,000.00. Following the sale, the insider owned 52,324 shares of the company’s stock, valued at approximately $4,185,920. This represents a 8.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 131,221 shares of company stock worth $10,239,760 in the last 90 days. Company insiders own 3.76% of the company’s stock.

Institutional Investors Weigh In On Disc Medicine

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in Disc Medicine in the 2nd quarter valued at about $180,502,000. Wellington Management Group LLP raised its stake in Disc Medicine by 0.3% during the 2nd quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company’s stock valued at $127,362,000 after acquiring an additional 5,975 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Disc Medicine by 191.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company’s stock worth $73,280,000 after acquiring an additional 735,300 shares during the period. Opaleye Management Inc. lifted its position in Disc Medicine by 103.1% during the 2nd quarter. Opaleye Management Inc. now owns 855,000 shares of the company’s stock worth $62,535,000 after acquiring an additional 434,000 shares during the period. Finally, BVF Inc. IL acquired a new stake in Disc Medicine during the 4th quarter worth approximately $51,616,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Disc Medicine Stock Up 0.7%

IRON opened at $79.48 on Friday. The business’s 50-day simple moving average is $71.53 and its 200-day simple moving average is $71.39. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14. Disc Medicine has a one year low of $40.00 and a one year high of $99.50. The stock has a market capitalization of $3.05 billion, a P/E ratio of -12.08 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating the consensus estimate of ($1.71) by $0.17. Analysts anticipate that Disc Medicine will post -6.61 EPS for the current year.

Key Headlines Impacting Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: APOLLO Phase 3 trial met all key objectives. Disc Medicine reported that bitopertin achieved every primary and secondary endpoint in patients with erythropoietic protoporphyria (EPP), including X-linked protoporphyria. The results strengthen the drug’s prospects and support management’s plan to resubmit it for FDA approval by year-end. Disc Medicine’s rare disease drug succeeds in late-stage trial
• Positive Sentiment: Analyst price target raised substantially. Cantor Fitzgerald increased its target for IRON to $170 from $125 and maintained an Overweight rating, citing the Phase 3 results. The revision reflects improved confidence in bitopertin’s regulatory and commercial potential. Disc Medicine price target raised by Cantor Fitzgerald
• Positive Sentiment: The trial improves the company’s strategic position. The successful readout potentially revives FDA approval hopes for bitopertin, Disc Medicine’s lead asset, and may reduce the valuation discount previously associated with clinical and regulatory risk.
• Neutral Sentiment: Investor debate has shifted from clinical success to valuation. Analysts and market commentators are assessing how much upside remains after the sharp rally and whether the current valuation fully reflects bitopertin’s approval and commercial prospects. Disc Medicine: APOLLO changes the story
• Negative Sentiment: Disc Medicine launched a proposed $350 million public offering of common stock and pre-funded warrants after the positive data. The financing should strengthen its cash position for development and commercialization, but issuing shares or warrants could dilute existing shareholders and limit near-term gains. Disc Medicine announces proposed $350 million public offering
• Negative Sentiment: Unusually heavy put-option activity indicates some traders are positioning for downside or increased volatility following the rally. This is a market signal rather than a fundamental change in the business.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.

The company’s pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.